<DOC>
	<DOCNO>NCT00003132</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness bryostatin 1 plus cisplatin treating patient metastatic unresectable cancer .</brief_summary>
	<brief_title>Bryostatin 1 Plus Cisplatin Treating Patients With Metastatic Unresectable Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose dose limit toxicity bryostatin 1 combination cisplatin patient advanced malignancy . II . Determine recommend phase II dose bryostatin 1 cisplatin 21 day 14 day course , base toxicity , effect protein kinase C activity , pharmacokinetics , patient population . III . Determine pharmacokinetics bryostatin 1 patient . IV . Identify objective tumor response arise treatment patient . OUTLINE : This dose escalation study bryostatin 1 . Cohorts 1-7 : Patients receive cisplatin IV 1 hour day 1 first course . Subsequent course repeat every 21 day bryostatin 1 IV 24 hour day 1 cisplatin IV 1 hour day 2 absence disease progression unacceptable toxicity . Cohorts 8-10 : Patients receive cisplatin cohort 1-7 . Subsequent course repeat every 21 day bryostatin 1 IV 1 hour follow cisplatin day 1 . Cohort 11 : Patients receive bryostatin 1 cisplatin cohort 8-10 . Cohorts 3-6 patient receive escalate dos bryostatin 1 cisplatin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience DLT . The recommended phase II dose ( RPTD ) define dose precede MTD . After RPTD determine 21 day schedule , cohorts patient receive escalate dos bryostatin constant dose cisplatin 14 day schedule . The MTD14 RPTD14 determine manner . Patients follow 6 month . PROJECTED ACCRUAL : A total 36-72 patient accrue study .</detailed_description>
	<mesh_term>Bryostatin 1</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic unresectable malignant disease Prior brain metastasis residual sign symptom medication allow PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) AST/ALT great 2.5 time ULN Alkaline phosphatase great 2.5 time ULN Renal : Creatinine great 1.5 mg/dL Other : Not pregnant nursing Fertile patient must use effective contraception No concurrent condition would preclude study No psychological , familial , sociological , geographical condition might compromise medical follow No neuropathy great grade 1 , include hearing loss PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 3 week since prior chemotherapy ( 6 week mitomycin nitrosoureas ) recover Prior cisplatin allow Endocrine therapy : Not specify Radiotherapy : At least 2 week since prior radiotherapy Prior radiotherapy brain metastasis allow Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>